Predictors of therapeutic response to peginterferon α‑2a and nucleos(t)ide analog combination therapy for HBeAg‑negative chronic hepatitis B: 1‑year follow‑up after treatment

  • Authors:
    • Shima Mimura
    • Koji Fujita
    • Kei Takuma
    • Mai Nakahara
    • Kyoko Oura
    • Tomoko Tadokoro
    • Joji Tani
    • Asahiro Morishita
    • Masafumi Ono
    • Takashi Himoto
    • Tsutomu Masaki
  • View Affiliations

  • Published online on: November 3, 2023     https://doi.org/10.3892/etm.2023.12286
  • Article Number: 587
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Chronic hepatitis B (CHB) is a major global health concern. Guidelines for the management of hepatitis B virus (HBV) indicate that the loss of hepatitis B surface antigen (HBsAg) is a key endpoint of interest. The present study aimed to examine long‑term changes in HBsAg levels in HBV‑DNA‑negative, hepatitis B e‑antigen (HBeAg)‑negative patients treated with peginterferon (Peg‑IFN) α‑2a and nucleos(t)ide analog (NA), and to examine the conditions that make them susceptible to HBsAg decline. A total of 17 patients with CHB treated with NA and Peg‑IFN were observed for 96 weeks (48 weeks of Peg‑IFN therapy and 48 weeks of post‑treatment follow‑up). In this study, responders were defined as those with a 50% or greater decrease in HBsAg levels from baseline at week 96. Beginning at week 16 of Peg‑IFN therapy, there was a significant difference in the decrease in HBsAg levels from baseline between the responders and non‑responders. In responders, HBsAg levels tended to be >60% lower 16 weeks after Peg‑IFN initiation than before initiation. Age at the start of NA use and the duration of NA use before Peg‑IFN treatment initiation were significant pretreatment factors associated with HBsAg response. In conclusion, Peg‑IFN was revealed to be more effective in HBeAg‑negative patients with CHB who started NA at a young age and have been on long‑term treatment, particularly if the HBsAg levels decreased to less than 60% of the starting level at week 16 after starting Peg‑IFN treatment.
View Figures
View References

Related Articles

Journal Cover

December-2023
Volume 26 Issue 6

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Mimura S, Fujita K, Takuma K, Nakahara M, Oura K, Tadokoro T, Tani J, Morishita A, Ono M, Himoto T, Himoto T, et al: Predictors of therapeutic response to peginterferon α‑2a and nucleos(t)ide analog combination therapy for HBeAg‑negative chronic hepatitis B: 1‑year follow‑up after treatment. Exp Ther Med 26: 587, 2023.
APA
Mimura, S., Fujita, K., Takuma, K., Nakahara, M., Oura, K., Tadokoro, T. ... Masaki, T. (2023). Predictors of therapeutic response to peginterferon α‑2a and nucleos(t)ide analog combination therapy for HBeAg‑negative chronic hepatitis B: 1‑year follow‑up after treatment. Experimental and Therapeutic Medicine, 26, 587. https://doi.org/10.3892/etm.2023.12286
MLA
Mimura, S., Fujita, K., Takuma, K., Nakahara, M., Oura, K., Tadokoro, T., Tani, J., Morishita, A., Ono, M., Himoto, T., Masaki, T."Predictors of therapeutic response to peginterferon α‑2a and nucleos(t)ide analog combination therapy for HBeAg‑negative chronic hepatitis B: 1‑year follow‑up after treatment". Experimental and Therapeutic Medicine 26.6 (2023): 587.
Chicago
Mimura, S., Fujita, K., Takuma, K., Nakahara, M., Oura, K., Tadokoro, T., Tani, J., Morishita, A., Ono, M., Himoto, T., Masaki, T."Predictors of therapeutic response to peginterferon α‑2a and nucleos(t)ide analog combination therapy for HBeAg‑negative chronic hepatitis B: 1‑year follow‑up after treatment". Experimental and Therapeutic Medicine 26, no. 6 (2023): 587. https://doi.org/10.3892/etm.2023.12286